Vylor is putting gene editing at the centre of its regulatory strategy as the company prepares to operate independently from Corteva. Teresa Babuscio, Head of Government and Industry Affairs for EMEA and APAC, discusses Europe's evolving NGT framework, international trade, biofuels and the policy priorities shaping Vylor's future.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.